We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.45 | 3.40 | 3.50 | 3.45 | 3.45 | 3.45 | 1,543,287 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -2.37M | -0.0262 | -1.32 | 3.11M |
From Apr 2019 to Apr 2024
TIDMVAL
RNS Number : 4819Y
ValiRx PLC
06 December 2017
VALIRX PLC
("ValiRx" or "the Company")
SHAREHOLDER CIRCULAR AND NOTICE OF GENERAL MEETING
London, UK, 6 December 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology announces that it has recently published and posted to shareholders a circular and notice convening a General Meeting of ValiRx Plc to be held at the offices of DAC Beachcroft LLP at 100 Fetter Lane, London EC4A 1BN at 9:00 a.m. on 21 December 2017.
The directors will propose at the General Meeting shareholder resolutions seeking shareholder authority to allot shares and the dis-application of pre-emptive rights.
A copy of the Circular will be available on the Company's website shortly: www.valirx.com
- ENDS -
For more information, please contact:
Hot Features
Premium
ValiRx plc Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka, Chief Executive www.valirx.com
Tarquin Edwards, Investor Relations Tel: +44 (0) 7879 458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 0880
Liam Murray / Jo Turner
Beaufort Securities Limited (Broker) Tel: +44 (0) 20 7382 8300
Jon Belliss
Notes for Editors
About ValiRx Plc
ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.
ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTABRTMBJMBJR
(END) Dow Jones Newswires
December 06, 2017 02:00 ET (07:00 GMT)
1 Year Valirx Chart |
1 Month Valirx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
